ResMed (RMD) Rose 15% in Q3
Fidelity Investments, an investment management company, recently released its “Fidelity Growth Strategies Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
Resmed Inc (RMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 1,056,200 | $257,839,544 | 0.92% | ||
| 2. | Greenvale Capital Bruce Emery | 700,000 | $170,884,000 | -4% | 9.75% |
| 3. | Coatue Management Philippe Laffont | 473,179 | $115,512,457 | 0.42% | |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 403,472 | $98,495,585 | -1% | 0.11% |
| 5. | Millennium Management Israel Englander | 389,202 | $95,011,992 | -11% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.13 | 2,487 | Director | 19,216 | 2016-08-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $244.23 | 1,000 | Officer | 93,864 | 2024-12-09 | Filing | |
| $245.65 | 2,000 | Director | 81,218 | 2024-12-04 | Filing | |
| $248.91 | 74 | Officer | 9,113 | 2024-12-02 | Filing | |
| $249.67 | 2,000 | Officer | 0 | 2024-11-27 | Filing | |
| $243.09 | 6,160 | Officer | 21,718 | 2024-11-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,743,457 | $3,052,229,474 | 0.06% | |
| 2. | 12,248,180 | $2,106,931,925 | 0.05% | |
| 3. | 6,290,089 | $1,082,021,110 | 0.05% | |
| 4. | 3,435,280 | $589,462,559 | 0.06% | |
| 5. | 2,529,218 | $435,076,071 | 0.03% |
News See All
ResMed Inc. (NYSE:RMD) Q1 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Q1 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call.
ResMed Inc. (NYSE:RMD) Q4 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Q4 Fiscal Year 2024 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call.
ResMed Inc. (NYSE:RMD) Q3 2024 Earnings Call Transcript
ResMed Inc. beats earnings expectations. Reported EPS is $2.13, expectations were $1.91. ResMed Inc.
20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world.
25 Most Valuable Medical Device Companies in the US
In this article, we will be taking a look at the 25 most valuable medical device companies in the US.
ResMed Inc. (NYSE:RMD) Q2 2024 Earnings Call Transcript
Operator: Hello, and welcome to the ResMed Second Quarter Fiscal Year 2024 Earnings Conference Call and Webcast.
ResMed Inc. (NYSE:RMD) Q1 2024 Earnings Call Transcript
Operator: Hello, and welcome to the ResMed First Quarter Fiscal Year 2024 Earnings Conference Call and Webcast [Operator Instructions]. As a reminder, this conference is being recorded.
5 Oversold Healthcare Stocks to Buy
Root, Switzerland-based NovoCure Limited (NASDAQ:NVCR) is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization...
5 Oversold Growth Stocks To Buy
In this piece, we will take a look at the five oversold growth stocks to buy.